Neo-adjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer treatment - A retrospective study;Neo-adjuvantná chemoterapia s následnou IDS (interval debulking surgery) v liečbe pokročilého karcinómu ovária - Retrospektívna analýza

Klinicka Onkologie

Volumn 22, Issue 6, 2009, Pages 273-277

  Tkáčová, Marcela ^a,b   Vertakova Krakovska B ^a,b   Belohorska B ^a,b   Miskovska V ^a,b   Hel'pianska, L ^a,b   Ondrus D ^a   Ondrusova M ^c,d   Spanik S ^a,b   Svec J ^a  

^a LF UK a OÚSA ^*  (Slovakia)

^b Interna onkologicka klinika OUSA a TU   (Slovakia)

^c INSTITUTE OF CHEMISTRY   (Slovakia)

^d MASARYK UNIVERSITY   (Czech Republic)

Author keywords

Chemotherapy; Neoadjuvant therapy; Ovarian cancer; Surgery

Indexed keywords

CARBOPLATIN; PACLITAXEL;

AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER SIZE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; FEMALE; HUMAN; OVARY CANCER; PROGNOSIS; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; OVARIAN NEOPLASMS; PACLITAXEL; SURVIVAL RATE;

EID: 75649146307     PISSN: 0862495X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Safaei Diba Ch, Pleško I, Obšitniková A et al. Incidencia zhubných nádorov v Slovenskej republike 2005. Národný onkologický register SR, NCZI 2009.
2. Deo SVS, Hemant G, Shukla NK et al. Neoadjuvant chemotherapy followed by surgical cytoreduction in advanced epithelial ovarian cancer. Indian J Cancer 2006; 43(3): 117-121.
3. Vergote IB. Neoadjuvant chemotherapy in advanced ovarian cancer. American Society of Clinical Oncology. Educational Book 2004; 285-291.
4. Rose PG. Neoadjuvant chemotherapy for ovarian cancer. American Society of Clinical Oncology. Educational Book 2004; 276-284.
5. Bristow RE,Tomacruz RS, Armstrong DK et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a metaanalysis. J Clin Oncol 2002; 20(5): 1248-1259.
6. Fader AN, Rose PG. Role of Surgery in Ovarian Cancer. J Clin Oncol 2007; 25(20): 2873-2880.
7. Le T, Shahriari L, Hopkins W et al. Prognostic significance of tumor necrosis in ovarian cancer patients treated with neoadjuvant chemotherapy and interval surgical debulking. Int J Gynecol Cancer 2006; 16(3): 986-990.
8. Vergote I, De Wever I, Tjalma W et al. Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients. Gynecol Oncol 1998; 71(3): 431-436.
9. Ansquer Y, Leblanc E, Clough K et al. Neoadjuvant chemotherapy for unresectable ovarian carcinoma-a French multicenter study. Cancer 2001; 91(12): 2329-2334.
10. Kuhn W, Rutke S, Späthe K et al. Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma. Cancer 2001; 92(10): 2585-2591.
11. Kayikcioglu F, Kose MF, Boran N et al. Neadjuvant chemotherapy or primary surgery in advanced epithelial ovarian carcinoma. Int J Gynecol Cancer 2001; 11(6): 466-470.
12. Mazzeo F, Berliere M, Kerger J et al. Neoadjuvant chemotherapy followed by surgery and adjuvant chemotherapyin patients with primarily unresectable, advanced-stage ovarian cancer. Gynecol Oncol 2003; 90(1): 163-169.
13. Krasner C, Duska L. Management of Women With Newly Diagnosed Ovarian cancer. Seminars in Oncology: Gynecol Cancer Update 2009; 36(2): 91-101.
14. Vergote I, van Gorp T, Amant F et al. Timing of debulking surgery in advanced ovarian cancer. Int J Gynecol Cancer 2008, 18 (Suppl 1): 11-19.
15. Thigpen T. The If and when of surgical debulking for ovarian carcinoma. N Engl J Med 2004; 351(24): 2544-2546.
16. Tesařik Z. Kontroverze v moderní léčbě pokročilého ovariálního karcinomu. Klin Onkol 2002; 15(4): 136-141.
17. Vergote I, van Gorp T, Amant F et al. Neoadjuvant chemotherapy for ovarian cancer. Oncology (Williston Park) 2005; 1902): 1615-1622.